Skip to Content
Merck
CN

Key Documents

View All Documentation

B0125

Bacitracin

from Bacillus licheniformis, ≥65 IU/mg

Synonym(s):

Altracin, Bacitracin A

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C66H103N17O16S
CAS Number:
1405-87-4
Molecular Weight:
1422.69
NACRES:
NA.76
PubChem Substance ID:
24891503
UNSPSC Code:
51282002
EC Number:
215-786-2
MDL number:
MFCD00062640
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

biological source

Bacillus licheniformis

Quality Level

200

form

powder

specific activity

≥65 IU/mg

antibiotic activity spectrum

Gram-positive bacteria

mode of action

cell wall synthesis | interferes

storage temp.

2-8°C

SMILES string

[H]N1[C@@H](Cc2cnc[nH]2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC[C@H](NC(=O)[C@@H](NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)C3CSC(=N3)C(N)C(C)CC)[C@@H](C)CC)C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](Cc4ccccc4)C1=O

InChI

1S/C66H103N17O16S/c1-9-35(6)52(69)66-81-48(32-100-66)63(97)76-43(26-34(4)5)59(93)74-42(22-23-50(85)86)58(92)83-53(36(7)10-2)64(98)75-40-20-15-16-25-71-55(89)46(29-49(68)84)78-62(96)47(30-51(87)88)79-61(95)45(28-39-31-70-33-72-39)77-60(94)44(27-38-18-13-12-14-19-38)80-65(99)54(37(8)11-3)82-57(91)41(21-17-24-67)73-56(40)90/h12-14,18-19,31,33-37,40-48,52-54H,9-11,15-17,20-30,32,67,69H2,1-8H3,(H2,68,84)(H,70,72)(H,71,89)(H,73,90)(H,74,93)(H,75,98)(H,76,97)(H,77,94)(H,78,96)(H,79,95)(H,80,99)(H,82,91)(H,83,92)(H,85,86)(H,87,88)/t35?,36-,37-,40-,41+,42+,43-,44+,45-,46-,47+,48?,52?,53-,54-/m0/s1

InChI key

CLKOFPXJLQSYAH-RNHDWVCBSA-N

General description

Chemical structure: peptide

Application

Bacitracin is used to study disruption of bacterial cell wall synthesis at the level of peptidoglycan cross-linking and isoprenyl metabolism.

Biochem/physiol Actions

Bacitracin is a peptide antibiotic.
Antimicrobial spectrum: Gram-positive bacteria.
Mode of Action: Inhibits bacterial cell wall synthesis by inhibiting dephosphorylation of lipid pyrophosphate.

Other Notes

Keep container tightly closed in a dry and well-ventilated place.

Still not finding the right product?

Explore all of our products under Bacitracin

Storage Class

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Regulatory Information

涉药品监管产品

This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000527320
0000527320
0000519631
0000519631
0000492390

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Articles

Inhibition of Cell Wall Biosynthesis by Antibiotics

β-lactam antibacterials inhibit transpeptidase enzymes, preventing peptidoglycan assembly in both Gram-positive and Gram-negative bacteria.

Related Content

Product Information Sheet - B0125

Product Information Sheet

Hiromasa Tsuda et al.
Antimicrobial agents and chemotherapy, 46(12), 3756-3764 (2002-11-19)
Streptococcus mutans is resistant to bacitracin, which is a peptide antibiotic produced by certain species of Bacillus. The purpose of this study was to clarify the bacitracin resistance mechanism of S. mutans. We cloned and sequenced two S. mutans loci
Kazuhiko Nakano et al.
Nature communications, 2, 485-485 (2011-09-29)
Although several risk factors for stroke have been identified, one-third remain unexplained. Here we show that infection with Streptococcus mutans expressing collagen-binding protein (CBP) is a potential risk factor for haemorrhagic stroke. Infection with serotype k S. mutans, but not
Pallavi Mandal et al.
The Lancet. Respiratory medicine, 2(6), 455-463 (2014-04-11)
Bronchiectasis is characterised by chronic cough, sputum production, and recurrent chest infections. Pathogenesis is poorly understood, but excess neutrophilic airway inflammation is seen. Accumulating evidence suggests that statins have pleiotropic effects; therefore, these drugs could be a potential anti-inflammatory treatment
View All Related Papers

Global Trade Item Number

SKUGTIN
B0125-1250KU04061833419496
B0125-50KU04061835542802
B0125-250KU04061835542796